Results: KRAS mutations were detected in 184 of 227 patients (81.1%) (G12D: 66; G12V: 65; G12R: 27; Q61:26) and were not detected in 43 patients (18.9%). KRAS mutations were associated with tumour ...

Written informed consent was obtained from all individuals participated in this study. HLA-A*02-restricted HBV-specific peptides, epitopes core 18-27 (FLPSDFFPSV) and polymerase 455-463 (GLSRYVARL) ...

A single systemic dose of SIL-204 sustained effective drug levels for over 56 days, targeting multiple KRAS mutations. Get two weeks of free access to pro-level trading tools, including news ...

SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by ~3-fold, tumor area ...

There are a significant number of words, phrases and acronyms that appear when talking about race and ethnicity which often change depending on the context of the conversation. Language is ...

Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.

Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

Pending phase 3 trial results, a biologics license application will be submitted for the KRAS-targeting cancer vaccine ELI-002. The FDA has provided supportive feedback in an end of phase 1 type B ...

1Department of Oncology, University of Oxford, Oxford, United Kingdom. *Corresponding Author: Connor E. Woolley, Department of Oncology, University of Oxford, Old Road Campus Research Building, ...

Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer.